Endo Continues To Expand Generics Business With Par Acquisition

After losing out on Salix to competitor Valeant, Endo makes a strong move into sterile injectables and other alternative dosage forms, and positions itself as the No. 5 generics firm in the U.S.

While it may have lost out on building out its brand business with gastrointestinal-focused Salix Pharmaceuticals Ltd., Endo International PLC is betting that its $8 billion buy-out of Par Pharmaceutical will not only expand its generic business but increase the growth rate in that unit with a focus on alternative dosage formulations and products that will be difficult for competitors to replicate.

Endo announced May 18 that it will acquire Par [See Deal], taken private by TPG Capital in 2012,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America